Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Webcasts|March 17, 2021

A Material Characterization Study for AAV Process Development and Tool Selection

Author(s)Entergris

***Live: Wednesday March 17, 2021 at 11am EDT| 8am PDT| 4pm GMT| 5pm CET *** Single-use material selection is a crucial element of process development for bioprocessing, and emerging viral vector-based therapies have special requirements. Learn about efforts to better understand the relationship of single-use material selection and process impact to improve yield. ***On Demand until March 17, 2022***

Register Free: https://www.biopharminternational.com/bp_w/aav

Event Overview:

The potential interaction of biologic materials with the containers used in bioprocessing and storage is a major concern. The evaluation and selection of suitable materials is essential. The growing adoption of adeno-associated virus (AAV) viral vectors in bioprocessing operations demand careful analysis of single-use bags and processing materials previously used for monoclonal antibody and recombinant protein bioprocessing.

In this webcast, experts from a materials supplier and contract manufacturing organization will review a case study that evaluated single-use bag material interaction and adsorptive relationship with AAV viral vector during storage. A review of the experimental methods, analytical approach, and results will present a frame of reference to help users better understand:

  • How material selection could impact process yields or development studies
  • Material selections that could minimize process and product interaction loss
  • The implications to development objectives by not selecting optimal materials

Q&A session will be provided

Key Learning Objectives:

  • Understand the potential impact of single-use bag selection on process outcomes
  • Review methodology to assess interaction between single-use bag and therapeutic product
  • Gain an understanding of the behavior of specific materials and their adsorptive effects with AAV viral vector

Speaker:

Joy Xiaohui Chen, Senior Applications Engineer, Entegris

Cari Sadowski, Principal Scientist, Fujifilm Diosynth Biotechnologies

Time and Date: Wednesday March 17, 2021 at 11am EDT| 8am PDT| 4pm GMT| 5pm CET

Sponsor: Entergris

Register Free: https://www.biopharminternational.com/bp_w/aav


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.